The findings of the clinical trial showed that CEA+ CRC patients tolerated the CEA CAR-T cell treatment even in high doses and that the majority of them showed some degree of therapeutic benefit [131,132,133]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.